Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 4
2006 1
2008 1
2012 1
2013 4
2015 1
2016 2
2017 2
2018 2
2019 3
2020 4
2021 4
2022 8
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Nationwide survey of refractory asthma with bronchiectasis by inflammatory subtypes.
Nomura N, Matsumoto H, Yokoyama A, Nishimura Y, Asano K, Niimi A, Tohda Y, Harada N, Nagase H, Nagata M, Inoue H, Kondo M, Horiguchi T, Miyahara N, Hizawa N, Hojo M, Hattori N, Hashimoto N, Yamasaki A, Kadowaki T, Kimura T, Miki M, Taniguchi H, Toyoshima M, Kawamura T, Matsuno O, Sato Y, Sunadome H, Nagasaki T, Oguma T, Hirai T; BEXAS study. Nomura N, et al. Respir Res. 2022 Dec 20;23(1):365. doi: 10.1186/s12931-022-02289-y. Respir Res. 2022. PMID: 36539765 Free PMC article.
Combination therapy with EGFR tyrosine kinase inhibitors and TEAD inhibitor increases tumor suppression effects in EGFR mutation-positive lung cancer.
Ogimoto T, Ozasa H, Tsuji T, Funazo T, Yamazoe M, Hashimoto K, Yoshida H, Hosoya K, Ajimizu H, Nomizo T, Yoshida H, Hamaji M, Menju T, Yoshizawa A, Date H, Hirai T. Ogimoto T, et al. Among authors: hashimoto k. Mol Cancer Ther. 2023 Dec 6. doi: 10.1158/1535-7163.MCT-23-0371. Online ahead of print. Mol Cancer Ther. 2023. PMID: 38052760
Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer.
Yamazoe M, Ozasa H, Tsuji T, Funazo T, Yoshida H, Hashimoto K, Hosoya K, Ogimoto T, Ajimizu H, Yoshida H, Itotani R, Sakamori Y, Kuninaga K, Aoki W, Hirai T. Yamazoe M, et al. Among authors: hashimoto k. Cancer Sci. 2023 Feb;114(2):546-560. doi: 10.1111/cas.15622. Epub 2022 Nov 23. Cancer Sci. 2023. PMID: 36285485 Free PMC article.
Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy-induced colitis.
Sakurai T, De Velasco MA, Sakai K, Nagai T, Nishiyama H, Hashimoto K, Uemura H, Kawakami H, Nakagawa K, Ogata H, Nishio K, Kudo M. Sakurai T, et al. Among authors: hashimoto k. Mol Oncol. 2022 Apr;16(7):1493-1507. doi: 10.1002/1878-0261.13062. Epub 2021 Jul 28. Mol Oncol. 2022. PMID: 34270845 Free PMC article.
38 results